Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBT Margin (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of EBT Margin data on record, last reported at 3.33% in Q4 2025.

  • For Q4 2025, EBT Margin rose 2118.0% year-over-year to 3.33%; the TTM value through Dec 2025 reached 4.11%, up 2169.0%, while the annual FY2025 figure was 4.11%, 2169.0% up from the prior year.
  • EBT Margin reached 3.33% in Q4 2025 per MIRM's latest filing, down from 1.99% in the prior quarter.
  • Across five years, EBT Margin topped out at 1825.75% in Q4 2021 and bottomed at 941.98% in Q3 2021.
  • Average EBT Margin over 5 years is 43.48%, with a median of 48.9% recorded in 2023.
  • The widest YoY moves for EBT Margin: up 75192bps in 2022, down -195580bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 1825.75% in 2021, then tumbled by -107bps to 130.05% in 2022, then soared by 61bps to 50.94% in 2023, then skyrocketed by 52bps to 24.51% in 2024, then soared by 86bps to 3.33% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 3.33% in Q4 2025, 1.99% in Q3 2025, and 4.27% in Q2 2025.